Craif Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
53
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$33.1M
- Investors
-
35
Craif General Information
Description
Developer of a biomarker analysis technology designed for the early detection of cancer and other diseases through liquid biopsy. The company utilizes a proprietary analysis foundation and artificial intelligence to analyze microRNA in urine and saliva, enabling healthcare providers to identify disease risks at early stages and provide personalized treatment options.
Contact Information
Website
www.craif.comCorporate Office
- THE PORTAL iidabashi B 1st Floor
- 8-30 Shin-Ogawacho, Shinjuku-ku
- Tokyo, 162-0814
- Japan
Corporate Office
- THE PORTAL iidabashi B 1st Floor
- 8-30 Shin-Ogawacho, Shinjuku-ku
- Tokyo, 162-0814
- Japan
Craif Timeline
Craif Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series D) | 18-Aug-2026 | $33.1M | Completed | Generating Revenue | ||
| 9. Accelerator/Incubator | 24-Dec-2025 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 27-Apr-2025 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 04-Mar-2025 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 29-May-2024 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 04-Mar-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 12-Apr-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 17-Jun-2020 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | $242K | Completed | Generating Revenue | |||
| 1. Seed Round | 17-Dec-2019 | $242K | $242K | Completed | Generating Revenue |
Craif Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B-class preferred | ||||||||
| A-1 Class Preferred | ||||||||
| Class A preferred | 16,250 | $328.64 | $328.64 | 1x | $328.64 | 16.8% | ||
| A-2 Class Preferred | 8,500 | $25.47 | $25.47 | 1x | $25.47 | 8.79% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Craif Comparisons
Industry
Financing
Details
Craif Competitors (12)
One of Craif’s 12 competitors is Ezra (Diagnostic Equipment), a Formerly VC-backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ezra (Diagnostic Equipment) | Formerly VC-backed | New York, NY | ||||
| FUJIFILM VisualSonics | Formerly VC-backed | Toronto, Canada | ||||
| UE LifeSciences | Venture Capital-Backed | Philadelphia, PA | ||||
| PathAI | Venture Capital-Backed | Boston, MA | ||||
| Micrima | Venture Capital-Backed | Bristol, United Kingdom |
Craif Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Craif Patents
Craif Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4606370-A1 | Method for fusing lipid nanoparticles | Pending | 21-Oct-2022 | ||
| EP-4606370-A4 | Method for fusing lipid nanoparticles | Pending | 21-Oct-2022 | ||
| US-20260258503-A1 | Method for fusing lipid nanoparticles | Pending | 21-Oct-2022 | ||
| WO-2024085247-A1 | Method for fusing lipid nanoparticles | Inactive | 21-Oct-2022 | ||
| EP-4491744-A1 | Primer set, kit for determining onset and/or onset risk of spinal muscular atrophy, and method for determining onset and/or onset risk of spinal muscular atrophy | Pending | 17-Oct-2022 | C07K14/4716 |
Craif Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Craif Investors (35)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Granite Asia | Venture Capital | Minority | ||
| North Pacific Bank | Corporation | Minority | ||
| SusHi Tech Tokyo | Accelerator/Incubator | |||
| 1955 Capital | Venture Capital | Minority | ||
| Aozora Corporate Investment | Corporate Venture Capital | Minority |
Craif FAQs
-
When was Craif founded?
Craif was founded in 2018.
-
Where is Craif headquartered?
Craif is headquartered in Tokyo, Japan.
-
What is the size of Craif?
Craif has 53 total employees.
-
What industry is Craif in?
Craif’s primary industry is Diagnostic Equipment.
-
Is Craif a private or public company?
Craif is a Private company.
-
What is Craif’s current revenue?
The current revenue for Craif is .
-
How much funding has Craif raised over time?
Craif has raised $75.6M.
-
Who are Craif’s investors?
Granite Asia, North Pacific Bank, SusHi Tech Tokyo, 1955 Capital, and Aozora Corporate Investment are 5 of 35 investors who have invested in Craif.
-
Who are Craif’s competitors?
Ezra (Diagnostic Equipment), FUJIFILM VisualSonics, UE LifeSciences, PathAI, and Micrima are some of the 12 competitors of Craif.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
